Policy Statement
Guanfacine for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents (*6-17 years old)

Policy Number
PCN 349-2018

Date of Issue
July - 2018

Review Date:
July - 2021
(Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)

Recommendations:
The PCN recommends guanfacine as a treatment option in line with NICE guidance below (NG87 - March 2018).

Offer atomoxetine or guanfacine to children aged 5 years* and over if
- they cannot tolerate methylphenidate or lisdexamfetamine or
- their symptoms have not responded to separate 6-week trials of lisdexamfetamine and methylphenidate, having considered alternative preparations and adequate doses.

Guanfacine will be considered AMBER on the traffic light system with initiation by specialists in secondary care only.

Key Considerations:
- NICE Clinical Guideline – Attention deficit hyperactivity disorder: diagnosis and management (NG87 – March 2018).
- *At the time of [NICE] publication (March 2018), atomoxetine or guanfacine did not have a UK marketing authorisation for this indication in children aged 5 years. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.

Date taken to Prescribing Clinical Network
4th July 2018

Agreed by PCN members
13th July 2018

Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG), Crawley CCG and Horsham & Mid-Sussex CCG